Gender-specific Effects of Treatment with Lifestyle, Metformin or Sulfonylurea on Glycemic Control and Body Weight: A German Multicenter Analysis on 9 108 Patients

Abstract

Effects of diabetes treatment are strongly connected to individual factors, but the relevant role of gender has not been addressed so far. This observational study evaluates whether monotherapy with lifestyle, metformin or sulfonylurea has gender-specific effects on glycemic control and/or body weight. Data of 9 108 patients with type 2 diabetes from 129 German diabetes centers were assessed by a standardized, prospective, computer-based diabetes care and outcome documentation system (DPV-Wiss-database; age 63.1±12.8 years, diabetes duration 5.7±7.4 years, HbA1c 55±17.7 mmol/mol [7.2±1.6%], BMI 30.6±6.1 kg/m², 49.3% female patients). Antidiabetic concepts included lifestyle intervention (n=5,787), metformin (n=2,180), sulfonylurea (n=943) or other antidiabetic drugs (n=198), respectively. HbA1c and body weight were compared before and after a stable monotherapeutical period of 0.8±0.4 years. Women had a significantly higher reduction of body weight after treatment with lifestyle (women−0.8±0.1 vs. men−0.2±0.1 kg; p<0.05), metformin (women−1.8±0.2 vs. men−1.2±0.2 kg; p<0.05) or sulfonylurea drugs (women−0.9±0.2 vs. men − 0.1±0.2 kg; p<0.05), whereas men displayed significantly higher HbA1c-reductions after treatment with lifestyle (women−6.9±0.2 mmol/mol [− 0.6±0.02%] vs. men−7.5±0.2 mmol/mol [0.7±0.02%]; p<0.05) and metformin only (women−6.3±0.3 mmol/mol [− 0.6±0.03%] vs. men − 7.4±0.3 mmol/mol [− 0.7±0.03%]; p<0.05). No differences were seen for sulfonylurea monotherapy concerning the HbA1c-reduction (women − 5.6±0.5 mmol/mol [− 0.5±0.05%] vs. men−6.4±0.4 mmol/mol [− 0.6±0.04%]; p=0.196). In summary, antidiabetic treatment concepts might result in gender-specific effects on body weight and HbA1c. Gender might therefore represent another important factor in the context of an individualized treatment management of type 2 diabetes.

Key words

type 2 diabetes - diabetes treatment - gender - body weight - glycemic control

• References

• 1 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596
• 2 Melloni C, Berger JS, Wang TY et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes 2010; 3: 135-142
• 3 Mosca L, Banka CL, Benjamin EJ et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol 2007; 49: 1230-1250
• 4 Zhang Y, Zitsman JL, Hou J et al. Fat cell size and adipokine expression in relation to gender, depot, and metabolic risk factors in morbidly obese adolescents. Obesity 2014; 22: 691-697
• 5 Legato MJ, Gelzer A, Goland R et al. Writing group for the partnership for gender-specific medicine. Gender-specific care of the patient with diabetes: review and recommendations. Gend Med 2006; 3: 131-158
• 6 Schunk M, Reitmeir P, Schipf S et al. Health-related quality of life in subjects with and without Type 2 diabetes: Pooled analysis of five population-based surveys in Germany. Diabetic Medicine 2012; 29: 646-653
• 7 Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332: 73-78
• 8 Göbl CS, Brannath W, Bozkurt L et al. Sex-specific differences in glycemic control and cardiovascular risk factors in older patients with insulin-treated type 2 diabetes mellitus. Gend Med 2010; 7: 593-599
• 9 Kautzky-Willer A, Handisurya A. Metabolic diseases and associated complications: Sex and gender matter. Eur J Clin Invest 2009; 39: 631-648
• 10 Booth GL, Kapral MK, Fung K et al. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006; 368: 29-36
• 11 Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011; 34: 1431-1437
• 12 Bilezikian JP, Josse RG, Eastell R et al. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013; 98: 1519-1528
• 13 Geerlings S, Fonseca V, Castro-Diaz D et al. Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 2014; 103: 373-381
• 14 Schütt M, Fach EM, Seufert J et al. DPV Initiative and the German BMBF Competence Network Diabetes Mellitus. Multiple complications and frequent severe hypoglycaemia in ‘elderly’ and ‘old’ patients with Type 1 diabetes. Diabet Med 2012; 29: e176-e179
• 15 Hanas R, John G. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Diabetes Care 2010; 33: 1903-1904
• 16 Westfall PH, Tobias RD, Wolfinger RD. Multiple comparisons and multiple tests using SAS. 2^nd Edition SAS Institute; 2011
• 17 Golay A. Metformin and body weight. Int J Obes 2008; 32: 61-72
• 18 Morrison F, Shubina M, Turchin A. Lifestyle counseling in routine care and long-term glucose, blood pressure, and cholesterol control in patients with diabetes. Diabetes Care 2012; 35: 334-341
• 19 Norris SL, Engelgau MM, Narayan KM. Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials. Diabetes Care 2001; 24: 561-587
• 20 Mittendorfer B, Magkos F, Fabbrini E et al. Relationship between body fat mass and free fatty acid kinetics in men and women. Obesity 2009; 17: 1872-1877
• 21 Held C, Iqbal R, Lear SA et al. Physical activity levels, ownership of goods promoting sedentary behaviour and risk of myocardial infarction: results of the INTERHEART study. Eur Heart J 2012; 33: 452-466
• 22 Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885
• 23 DECODE Study Group . Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 2003; 26: 61-69
• 24 Anderwald C, Tura A, Winhofer Y et al. Glucose absorption in gestational diabetes mellitus during an oral glucose tolerance test. Diabetes Care 2011; 34: 1475-1480
• 25 Zhou K, Donnelly L, Yang J et al. Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diabetes Endocrinol 2014; 2: 481-487
• 26 Williams LK, Padhukasahasram B, Ahmedani BK et al. Differing effects of metformin on glycemic control by race-ethnicity. J Clin Endocrinol Metab 2014; 99: 3160-3168
• 27 Selvin E, Bolen S, Yeh HC et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008; 168: 2070-2080
• 28 Lim CT, Kola B, Korbonits M. AMPK as a mediator of hormonal signalling. J Mol Endocrinol 2010; 44: 87-97
• 29 Lyons MR, Peterson LR, McGill JB et al. Impact of sex on the heart’s metabolic and functional responses to diabetic therapies. Am J Physiol Heart Circ Physiol 2013; 305: H1584-H1591